You may trust your doctor to keep up to date with the latest treatments for diabetes, but a new poll shows that many doctors struggle to stay informed on all the new drugs and devices entering the market. In a recent survey, 149 endocrinologists about a new drug ertugliflozin. (At the time of the survey, the FDA was considering approval of the drug for type 2; it is now approved.) Ertugliflozin met the primary outcomes in two year-long phase 3 trials, VERTIS SU and VERTIS SITA2, but only 45% of the physicians said they had heard of the drug. Of those, 20% knew it only by name and only 5% were “very familiar” with it. Read more